Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 13/20 | 0.68 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.62 |
| ▸ | HRH1 | P35367 | 1/20 | 0.62 |
| ▸ | HTR1D | P28221 | 3/20 | 0.59 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1681047 | 0.94 | KCNA3 (0.69) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL8662664 | 0.93 | KCNA3 (0.67) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL1772505 | 0.93 | KCNA3 (0.67) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL2204553 | 0.90 | HTR1B (0.67) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL9770352 | 0.88 | KCNA3 (0.81) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL2177350 | 0.88 | HTR1B (0.78) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL16902853 | 0.86 | KCNA3 (0.79) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL16902840 | 0.86 | KCNA3 (0.79) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL16902852 | 0.86 | KCNA3 (0.79) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL16902855 | 0.86 | KCNA3 (0.79) | HTR1BKCNA3SLC6A4HRH1HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954193-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| CN-108745414-B | Application of alcohol amine ionic liquid in catalysis of nucleophilic fluorination reaction in aqueous phase system | 河南师范大学 | 2020-12-01 | — | — | CN | disclosed |
| EP-3038618-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3243814-B1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20180258039-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2018-09-13 | — | — | US | disclosed |
| US-10005728-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3243814-A1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | AbbVie Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2134684-B1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9551928-B2 | Actinic-ray- or radiation-sensitive resin composition and method of forming pattern therewith | FUJIFILM CORPORATION (JP) | 2017-01-24 | — | — | US | disclosed |
| US-9551928-B2 | Actinic-ray- or radiation-sensitive resin composition and method of forming pattern therewith | FUJIFILM CORPORATION (JP) | 2017-01-24 | — | — | US | disclosed |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008130970-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-0342664-B1 | 2,2-disubstituted benzopyran leukotriene-D4 antagonists | SEARLE & CO (US) | 1993-12-15 | — | — | EP | disclosed |
| US-5093353-A | 2,2-di-substituted benzopyran leukotriene-D4 antagonists | G. D. SEARLE & CO. (US) | 1992-03-03 | — | — | US | disclosed |
| EP-0342664-A2 | 2,2-disubstituted benzopyran leukotriene-D4 antagonists | G.D. Searle & Co. (US) | 1989-11-23 | — | — | EP | disclosed |
| EP-0044940-B1 | AMINO-DESOXY-1.4;3.6-DIANHYDRO-HEXITE NITRATES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | Dr. Willmar Schwabe GmbH & Co. (DE) | 1984-09-19 | — | — | EP | disclosed |
| US-4363805-A | TREATMENT OF CORONARY DISEASE | FIRMA WILLMAR SCHWABE (DE) | 1982-12-14 | — | — | US | disclosed |
| EP-0044940-A1 | Amino-desoxy-1.4;3.6-dianhydro-hexite nitrates, processes for their preparation and pharmaceutical compositions | Dr. Willmar Schwabe GmbH & Co. (DE) | 1982-02-03 | — | — | EP | disclosed |
| US-4260816-A | HYPOGLYCEMIC, HYPOLIPIDEMIC AGENTS, TREATMENT OF DIABETES | AMERICAN CYANAMID COMPANY (US) | 1981-04-07 | — | — | US | disclosed |
| US-3997667-A | HYPOTENSIVE | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180258039-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2, BCL2L1 | HTR1B 1091/4885KCNA3 2797/4885SLC6A4 4024/4885 |
| US-10005728-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2, BCL2L1 | HTR1B 1091/4885KCNA3 2797/4885SLC6A4 4024/4885 |
| US-10954193-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2, BCL2L1 | HTR1B 1091/4885KCNA3 2797/4885SLC6A4 4024/4885 |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | HTR1B 2400/4885KCNA3 4270/4885SLC6A4 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.